Tandem Diabetes Care, Inc. (TNDM) P/E Ratio History
Historical price-to-earnings valuation from 2021 to 2022
Loading P/E history...
TNDM Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 7, 2026, Tandem Diabetes Care, Inc. (TNDM) trades at a price-to-earnings ratio of -5.9x, with a stock price of $18.03 and trailing twelve-month earnings per share of $-3.01.
The current P/E is 101% below its 5-year average of 1125.7x. Over the past five years, TNDM's P/E has ranged from a low of 412.8x to a high of 1979.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, TNDM trades at a 127% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, TNDM trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TNDM DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TNDM P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $11B | 43.4 | 0.42 | -40% | |
| $23B | 28.9 | 2.76 | +47% | |
| $363B | 86.5 | - | -1% | |
| $99B | 21.5 | - | +31% | |
| $203B | 12.7 | 0.61 | +2% | |
| $933B | 43.0 | 1.49 | +96% | |
| $2B | 6.8Lowest | 0.66 | +817%Best | |
| $150B | 11.3 | 0.38Best | +134% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
TNDM Historical P/E Data (2021–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q1 | $116.29 | $0.08 | 1453.6x | +29% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $150.52 | $0.23 | 656.7x | -42% |
| FY2021 Q3 | $119.38 | $0.29 | 412.8x | -63% | |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $97.40 | $0.05 | 1979.7x | +76% |
Average P/E for displayed period: 1125.7x
See TNDM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TNDM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TNDM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTNDM — Frequently Asked Questions
Quick answers to the most common questions about buying TNDM stock.
Is TNDM stock overvalued or undervalued?
TNDM trades at -5.9x P/E, below its 5-year average of 1125.7x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does TNDM's valuation compare to peers?
Tandem Diabetes Care, Inc. P/E of -5.9x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is TNDM's PEG ratio?
TNDM PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2021-2022.